特异性和持久的蛋白酶体抑制决定了 marizomib 及其类似物诱导细胞凋亡。
Specific and prolonged proteasome inhibition dictates apoptosis induction by marizomib and its analogs.
机构信息
Department of Pediatrics Research, Children's Cancer Hospital at M.D. Anderson, University of Texas M.D. Anderson Cancer Center, Houston, United States.
出版信息
Chem Biol Interact. 2011 Oct 15;194(1):58-68. doi: 10.1016/j.cbi.2011.08.005. Epub 2011 Aug 16.
Abstract
Marizomib (NPI-0052) is a naturally derived irreversible proteasome inhibitor that potently induces apoptosis via a caspase-8 and ROS-dependent mechanism in leukemia cells. We aim to understand the relationship between the irreversible inhibition of the proteasome and induction of cell death in leukemia cells by using analogs of marizomib that display reversible and irreversible properties. We highlight the importance of sustained inhibition of at least two proteasome activities as being key permissive events for the induction of the apoptotic process in leukemia cells. These data provide the basis for the development of new approaches to generate more effective anti-proteasome therapies.
摘要
马利佐米（NPI-0052）是一种天然衍生的不可逆蛋白酶体抑制剂，通过半胱天冬酶-8 和 ROS 依赖性机制在白血病细胞中强烈诱导细胞凋亡。我们旨在通过使用具有可逆和不可逆特性的马利佐米类似物来了解蛋白酶体的不可逆抑制与白血病细胞死亡诱导之间的关系。我们强调了至少两种蛋白酶体活性的持续抑制作为诱导白血病细胞凋亡过程的关键许可事件的重要性。这些数据为开发新方法生成更有效的抗蛋白酶体治疗提供了基础。
相似文献
1
Specific and prolonged proteasome inhibition dictates apoptosis induction by marizomib and its analogs.特异性和持久的蛋白酶体抑制决定了 marizomib 及其类似物诱导细胞凋亡。
Chem Biol Interact. 2011 Oct 15;194(1):58-68. doi: 10.1016/j.cbi.2011.08.005. Epub 2011 Aug 16.
2
NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells.新型蛋白酶体抑制剂NPI-0052在白血病细胞中单独及与组蛋白去乙酰化酶抑制剂联合使用时，可诱导半胱天冬酶-8和活性氧依赖性凋亡。
Blood. 2007 Jul 1;110(1):267-77. doi: 10.1182/blood-2006-03-013128. Epub 2007 Mar 13.
3
Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.新型蛋白酶体抑制剂NPI-0052介导的半胱天冬酶8依赖性组蛋白乙酰化：白血病细胞协同作用机制
Blood. 2009 Apr 30;113(18):4289-99. doi: 10.1182/blood-2008-08-174797. Epub 2009 Jan 30.
4
The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia.蛋白酶体抑制剂NPI-0052在慢性淋巴细胞白血病患者的淋巴细胞中比硼替佐米更有效地诱导细胞凋亡。
Mol Cancer Ther. 2006 Jul;5(7):1836-43. doi: 10.1158/1535-7163.MCT-06-0066.
5
Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist.马利昔替尼可增强原发性神经胶质瘤细胞对最新一代 TRAIL 受体激动剂诱导的细胞凋亡的敏感性。
Cell Death Dis. 2021 Jun 24;12(7):647. doi: 10.1038/s41419-021-03927-x.
6
Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells.蛋白酶体抑制剂及其与组蛋白去乙酰化酶抑制剂联合使用对白血病细胞的抗增殖和促凋亡作用。
Cardiovasc Hematol Disord Drug Targets. 2009 Mar;9(1):62-77. doi: 10.2174/187152909787581372.
7
Synthesis of salinosporamide A and its analogs as 20S proteasome inhibitors and SAR summarization.沙利度胺类似物 A 的合成及其作为 20S 蛋白酶体抑制剂的应用及构效关系总结。
Curr Top Med Chem. 2011 Dec;11(23):2906-22. doi: 10.2174/156802611798281302.
8
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.一种新型口服活性蛋白酶体抑制剂通过不同于硼替佐米的机制诱导多发性骨髓瘤细胞凋亡。
Cancer Cell. 2005 Nov;8(5):407-19. doi: 10.1016/j.ccr.2005.10.013.
9
Proteasome regulator marizomib (NPI-0052) exhibits prolonged inhibition, attenuated efflux, and greater cytotoxicity than its reversible analogs.蛋白酶体调节剂马利佐米（NPI-0052）的抑制作用持久，外排减少，细胞毒性比其可逆类似物更强。
J Pharmacol Exp Ther. 2011 May;337(2):479-86. doi: 10.1124/jpet.110.177824. Epub 2011 Feb 8.
10
Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models.帕比司他和马利司他在急性髓系白血病和硼替佐米耐药模型中的疗效。
Leuk Res. 2015 Mar;39(3):371-9. doi: 10.1016/j.leukres.2014.12.014. Epub 2015 Jan 3.
引用本文的文献
1
Structural Insights into Salinosporamide a Mediated Inhibition of the Human 20S Proteasome.对盐孢菌素A介导的人20S蛋白酶体抑制作用的结构洞察
Molecules. 2025 Mar 20;30(6):1386. doi: 10.3390/molecules30061386.
2
The Proteasome Inhibitor Marizomib Evokes Endoplasmic Reticulum Stress and Promotes Apoptosis in Human Glioblastoma Cells.蛋白酶体抑制剂马立佐米可引发人胶质母细胞瘤细胞内质网应激并促进其凋亡。
Pharmaceuticals (Basel). 2024 Aug 20;17(8):1089. doi: 10.3390/ph17081089.
3
Combined treatment of marizomib and cisplatin modulates cervical cancer growth and invasion and enhances antitumor potential and .马立司他明与顺铂联合治疗可调节宫颈癌的生长和侵袭，并增强抗肿瘤潜力。
Front Oncol. 2022 Aug 30;12:974573. doi: 10.3389/fonc.2022.974573. eCollection 2022.
4
as a Transient Expression Host to Produce Auxin Analogs.作为生产生长素类似物的瞬时表达宿主。
Front Plant Sci. 2020 Nov 20;11:581675. doi: 10.3389/fpls.2020.581675. eCollection 2020.
5
Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.马立司他作为单一药物在恶性胶质瘤中的活性：穿越血脑屏障的能力。
Neuro Oncol. 2016 Jun;18(6):840-8. doi: 10.1093/neuonc/nov299. Epub 2015 Dec 17.
6
Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling.硼替佐米及新型蛋白酶体抑制剂对骨髓瘤细胞和骨微环境的作用机制：对骨髓瘤诱导的骨重塑改变的影响
Biomed Res Int. 2015;2015:172458. doi: 10.1155/2015/172458. Epub 2015 Oct 22.
7
Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.蛋白酶体抑制剂——多发性骨髓瘤的分子基础及当前研究进展
J Cell Mol Med. 2014 Jun;18(6):947-61. doi: 10.1111/jcmm.12279. Epub 2014 Apr 8.
本文引用的文献
1
Proteasome regulator marizomib (NPI-0052) exhibits prolonged inhibition, attenuated efflux, and greater cytotoxicity than its reversible analogs.蛋白酶体调节剂马利佐米（NPI-0052）的抑制作用持久，外排减少，细胞毒性比其可逆类似物更强。
J Pharmacol Exp Ther. 2011 May;337(2):479-86. doi: 10.1124/jpet.110.177824. Epub 2011 Feb 8.
2
Elevation of heme oxygenase-1 by proteasome inhibition affords dopaminergic neuroprotection.蛋白酶体抑制作用升高血红素加氧酶-1 水平，从而提供多巴胺能神经保护作用。
J Neurosci Res. 2010 Jul;88(9):1934-42. doi: 10.1002/jnr.22363.
3
Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.新型蛋白酶体抑制剂NPI-0052介导的半胱天冬酶8依赖性组蛋白乙酰化：白血病细胞协同作用机制
Blood. 2009 Apr 30;113(18):4289-99. doi: 10.1182/blood-2008-08-174797. Epub 2009 Jan 30.
4
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.离去基团可延长20S蛋白酶体抑制的持续时间并增强盐孢菌素的效力。
J Med Chem. 2008 Nov 13;51(21):6711-24. doi: 10.1021/jm800548b. Epub 2008 Oct 22.
5
NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells.新型蛋白酶体抑制剂NPI-0052在白血病细胞中单独及与组蛋白去乙酰化酶抑制剂联合使用时，可诱导半胱天冬酶-8和活性氧依赖性凋亡。
Blood. 2007 Jul 1;110(1):267-77. doi: 10.1182/blood-2006-03-013128. Epub 2007 Mar 13.
6
20S proteasome and its inhibitors: crystallographic knowledge for drug development.20S蛋白酶体及其抑制剂：药物研发的晶体学知识
Chem Rev. 2007 Mar;107(3):687-717. doi: 10.1021/cr0502504. Epub 2007 Feb 23.
7
The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia.蛋白酶体抑制剂NPI-0052在慢性淋巴细胞白血病患者的淋巴细胞中比硼替佐米更有效地诱导细胞凋亡。
Mol Cancer Ther. 2006 Jul;5(7):1836-43. doi: 10.1158/1535-7163.MCT-06-0066.
8
Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding.与20S蛋白酶体结合的盐霉素A（NPI-0052）和B（NPI-0047）的晶体结构揭示了β-内酯环开环的重要影响以及不可逆结合的机制。
J Am Chem Soc. 2006 Apr 19;128(15):5136-41. doi: 10.1021/ja058320b.
9
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.阿地福司汀诱导的氧化应激克服了BCR/ABL突变依赖性和非依赖性伊马替尼耐药性。
Blood. 2006 Mar 15;107(6):2501-6. doi: 10.1182/blood-2005-07-2966. Epub 2005 Nov 15.
10
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.一种新型口服活性蛋白酶体抑制剂通过不同于硼替佐米的机制诱导多发性骨髓瘤细胞凋亡。
Cancer Cell. 2005 Nov;8(5):407-19. doi: 10.1016/j.ccr.2005.10.013.
Zotero 插件